Research Guides / Semaglutide vs Tirzepatide: STEP, SURMOUNT, and What the Trials Show
9 min readTwo drugs. Same dosing schedule. Same injection route. Both approved for type 2 diabetes and chronic weight management. Both dominate the conversation around obesity pharmacology.
But they are not the same class of drug, and the difference between them explains why one consistently produces more weight loss than the other -- and why that difference is smaller than you might expect.
Semaglutide activates one receptor: GLP-1. That is the hormone your body releases after eating, and it does several things -- signals insulin release, suppresses glucagon, slows digestion, and reduces appetite through central pathways. Semaglutide mimics it with high affinity and, thanks to three coordinated modifications, a roughly seven-day half-life.
Tirzepatide activates two: GIP and GLP-1. GIP -- glucose-dependent insulinotropic polypeptide -- is released from the same intestinal cells that produce GLP-1. It also stimulates insulin release, but through a different receptor with different downstream effects, including a stronger signal to adipose tissue.
The question is not whether adding GIP does something. It does. The question is how much -- and at what cost.
GIP receptors are expressed on adipose tissue, bone, the brain, and the cardiovascular system. Their activation enhances insulin secretion in a glucose-dependent manner, similar to GLP-1, but also appears to improve insulin sensitivity independently -- an effect GLP-1 does not replicate. This dual insulin action (more secretion plus better sensitivity) is the leading explanation for tirzepatide's additional weight loss. The cost is a more complex pharmacological profile: two receptor systems producing on-target effects, off-target effects, and interactions that are still being mapped.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 (dual agonist) |
| Brand names | Ozempic (diabetes), Wegovy (weight) | Mounjaro (diabetes), Zepbound (weight) |
| Amino acids | 31 | 39 |
| Half-life | ~7 days | ~5 days |
| Dosing | Once weekly | Once weekly |
| Research status | Approved | Approved |
Semaglutide's weight-loss evidence comes from the STEP program -- a series of randomized, double-blind trials enrolling thousands of participants with obesity or overweight. The headline result: approximately 15% body-weight reduction at the 2.4 mg dose over 68 weeks in STEP 1. STEP 3 added intensive behavioral therapy to semaglutide, producing roughly 16% weight loss -- only marginally more than the drug alone, which is itself informative about how much of the effect is pharmacological versus behavioral.
Tirzepatide's evidence comes from SURMOUNT. Same structure: randomized, double-blind, large enrollment. The headline: approximately 20.9% body-weight reduction at the 15 mg dose over 72 weeks in SURMOUNT-1. SURMOUNT-3 added a 12-week lead-in period of intensive lifestyle intervention before starting the drug, showing that tirzepatide added significant weight loss on top of what lifestyle changes alone could achieve.
That 5-6 percentage-point gap is real, and it held up across multiple trials. In SURMOUNT-2, which specifically enrolled participants with type 2 diabetes (where weight loss is typically harder to achieve), tirzepatide produced roughly 15.9% at 10 mg versus semaglutide's roughly 9.6% at 1 mg in the comparable STEP 2 diabetic population.
But the comparison is not as clean as those numbers suggest.
| Dimension | STEP (Semaglutide) | SURMOUNT (Tirzepatide) |
|---|---|---|
| Primary population | Obesity/overweight with or without T2DM | Obesity/overweight with or without T2DM |
| Duration | 68 weeks | 72 weeks |
| Max dose studied | 2.4 mg | 15 mg |
| Primary endpoint | % body-weight change | % body-weight change |
| Blinding | Double-blind, placebo-controlled | Double-blind, placebo-controlled |
| Diabetic sub-study | STEP 2 (T2DM population) | SURMOUNT-2 (T2DM population) |
| Weight loss (non-diabetic) | ~15% at 2.4 mg | ~20.9% at 15 mg |
| Weight loss (diabetic) | ~9.6% at 1 mg | ~15.9% at 10 mg |
The dose scales are different (milligrams vs. tens of milligrams), the durations differ by four weeks, and the receptor pharmacology is not comparable in a simple way. A direct head-to-head trial -- where both drugs are tested in the same protocol with the same population -- would be the cleanest comparison. That trial (SURPASS) exists for the diabetes indication and showed tirzepatide producing superior A1c reduction. A head-to-head for weight loss in the non-diabetic population has not been completed.
Both drugs use dose escalation. Neither starts at its maximum. This is not caution for its own sake -- it is a response to the most common side effect.
Gastrointestinal intolerance -- nausea, vomiting, diarrhea, constipation -- is the dose-limiting factor for the entire GLP-1 class. Both drugs titrate upward over several weeks to give the body time to adjust. The escalation schedule is itself data: it tells you the threshold at which the drug becomes hard to tolerate and how the manufacturer chose to manage that.
Semaglutide's Wegovy label escalates over 16 weeks: 0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg, holding at each step for four weeks. Tirzepatide's Zepbound label escalates over roughly 20 weeks through a similar multi-step path to 15 mg.
The practical implication: more weight loss on tirzepatide means more time spent titrating and a higher absolute dose. The side-effect burden at the top of tirzepatide's range is not trivial. A meaningful fraction of participants in the SURMOUNT trials discontinued due to gastrointestinal events, and that fraction increased with dose.
The GIP receptor has been studied for decades, and its role in metabolism is more nuanced than GLP-1's. GIP stimulates insulin release strongly but also has tissue-specific effects on fat cells that GLP-1 does not replicate. The theory behind dual agonism is that engaging both receptors produces a broader metabolic shift: more insulin sensitization, greater energy expenditure, and a stronger appetite signal.
The SURMOUNT data supports that the shift is real. Where the theory is less clear is why the additional weight loss is roughly 5-6 points rather than 10 or 15. If GIP added a fully independent pathway, you might expect a larger gap. That it is moderate suggests either partial pathway overlap or that GIP's contribution is inherently bounded.
The tradeoff is also real. More receptor engagement means more opportunity for off-target effects and a more complex side-effect profile. GIP receptors exist on adipose tissue, bone, and the cardiovascular system, and engaging them alongside GLP-1 produces effects that are not fully predictable from either pathway alone.
Tirzepatide's SURPASS-2 trial -- the only head-to-head between the two drugs, conducted in a diabetic population -- showed tirzepatide producing superior A1c reduction and weight loss. But it compared tirzepatide 15 mg against semaglutide 1 mg, and semaglutide's maximum dose is 2.4 mg. The dose mismatch means the trial demonstrated that tirzepatide is more effective at its top dose than semaglutide is at its mid-range dose. That is meaningful, but it leaves open the question of what happens when both drugs are compared at their respective maximums.
Both drugs have cardiovascular outcome trials. Semaglutide's SELECT trial showed a 20% reduction in major adverse cardiovascular events in obese patients without diabetes -- a result that surprised many observers and expanded GLP-1's perceived scope well beyond glycemic control. That finding is supported by earlier SUSTAIN-6 data in diabetic patients, which showed a similar MACE reduction. Semaglutide also demonstrated kidney-protective effects in the FLOW trial, slowing eGFR decline and reducing kidney failure events. Together, these cardiovascular and renal outcomes give semaglutide a breadth of outcome data that no other drug in this class has yet matched.
Tirzepatide's SURPASS-CVOT trial is designed to answer the same question, with results anticipated to further clarify whether dual GIP/GLP-1 agonism confers cardiovascular benefits comparable to or exceeding GLP-1 alone. The cardiovascular data matters because it is the factor most likely to change prescribing patterns: a drug that treats both obesity and cardiovascular risk has a fundamentally different clinical position than one that treats only weight.
Whether tirzepatide's additional receptor engagement translates into additional cardiovascular protection -- or introduces new risks -- is what the ongoing trials will determine.
This article is educational and not medical advice. It describes published clinical trial results and does not recommend any compound, dose, or protocol. Semaglutide and tirzepatide are prescription medications; their use should be supervised by a qualified clinician. Decisions about any therapy belong with a qualified clinician who knows your history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.